Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. April 2026 08:30 ET | Quelle: BioMedWire

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value...
29. August 2025 15:13 ET | Quelle: Robbins LLP

SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action

Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug
18. August 2025 17:56 ET | Quelle: Robbins LLP

Robbins LLP Reminds Sarepta Therapeutics, Inc. Stockholders of the Pending Lead Plaintiff Deadline in the Securities Class Action Against SRPT

Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug
07. Juli 2025 17:24 ET | Quelle: Robbins LLP

Robbins LLP Reminds Sarepta Therapeutics, Inc. Investors with Large Losses to Contact the Firm for Information About the SRPT Class Action Lawsuit

Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug
03. Juli 2025 19:33 ET | Quelle: Robbins LLP

Sarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the Lead Plaintiff Deadline in the SRPT Class Action Lawsuit

Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug
30. Juni 2025 19:28 ET | Quelle: Robbins LLP

Shareholder Alert: Robbins LLP Informs Investors of the Sarepta Therapeutics, Inc. Class Action

Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug